Table 2. Adjusted Differences in AET Adherence (Proportion of Days Covered) Associated With Symptom Burden and Race.
| Model | Coefficient (95% CI) | ||
|---|---|---|---|
| Count of symptoms with ≥3-point increase, during AET | Count of moderate symptoms, baseline | Black (vs White) | |
| Baseline model onlya | NA | NA | 4.1 (–1.9 to 10.1) |
| Baseline model adjusted for symptom cluster | |||
| Gastrointestinal symptomsb | –1.1 (–2.4 to 0.1) | –1.6 (–3.2 to 0.0) | 4.0 (–2.0 to 9.9) |
| Gynecological symptomsb | 0.3 (–2.0 to 2.7) | –0.9 (–3.8 to 1.9) | 3.9 (–2.1 to 9.9) |
| Neuropsychological symptomsb | –1.4 (–2.9 to 0.2) | –1.8 (–3.4 to –0.2) | 3.9 (–2.0 to 9.9) |
| Vasomotor symptomsb | –2.0 (–3.8 to –0.3) | –2.0 (–3.9 to –0.1) | 4.2 (–1.7 to 10.1) |
| Musculoskeletal symptomsb | –1.2 (–2.4 to –0.1) | –1.3 (–2.3 to –0.2) | 3.7 (–2.2 to 9.7) |
| Integumentary symptomsb | –1.5 (–3.0 to 0.01) | –0.6 (–2.3 to 1.1) | 4.2 (–1.7 to 10.2) |
| Cardiorespiratory symptomsb | –2.5 (–4.4 to –0.6) | –0.3 (–2.5 to 1.9) | 3.8 (–2.1 to 9.8) |
| Distress symptomsb | –2.6 (–4.7 to –0.6) | –1.4 (–3.5 to 0.7) | 6.5 (0.1 to 12.8) |
| Despair symptomsb | –2.0 (–3.8 to –0.2) | –0.6 (–2.7 to 1.5) | 6.8 (0.5 to 13.2) |
Abbreviations: AET, adjuvant endocrine therapy; NA, not applicable.
a
Baseline model was also adjusted for sociodemographic characteristics (age at diagnosis, race, neighborhood-level education, neighborhood-level income, residence state) and clinical characteristics (cancer stage, history of chemotherapy). Full models are provided in eTable 4 and eTable 5 in the Supplement.
b
Models also were adjusted for sociodemographic characteristics and clinical characteristics in baseline model, as well as corresponding symptom cluster (eg, neuropsychological symptoms, vasomotor symptoms, musculoskeletal symptoms, cardiorespiratory symptoms, distress symptoms). Full models are provided in eTable 4 and eTable 5 in the Supplement.